Statin therapy may exacerbate underlying neuromuscular disorders. ‼️REMEMBER☝️The only ABSOLUTE contraindication to statins are pts who are HMGCR+ #ACR22 @RheumNow #acrreview https://t.co/A3XGHlrm0X

Interesting study by Dr Ai Li Yeo and colleagues on repetitive anti-dsDNA testing and flare prediction: 🔅Fluctuations (⬆️and ⬇️) in anti-dsDNA >2 fold was assoc'd w/⬆️flares in all groups including persistently + pts. #ACR22 @RheumNow ABST#327 https://t.co/q0WXnIwV4A

In this study, Dr. Niti Goel shows the under-reporting of race & ethnicity in publications of #psoriaticarthritis clinical trials 🧐Participant diversity is important to consider since different races & ethnicities may respond differently to therapies #ACR22 @RheumNow ABST0090 https://t.co/BzHpuHYVI5

Post hoc analysis from the SELECT-PsA 1 trial by Dr. @DrLauraCoates and team: 💊Pts on UPA showed greater improvement from BL in RAPID3 vs. ADA in all visits 💊Pts on UPA had better responses in all assessments vs. PBO Reassuring data. #ACR22 @RheumNow ABST0192 https://t.co/NgeUU5bPPf

Abstr 0383 evaluated the use of previously developed AI algorithm to detect sacroiliitis in a new axSpA cohort. The neural network achieved -Sensitivity 82%; specificity 81% -PPV 0.89; NPV 0.70 https://t.co/PDSsiMIQUc @RheumNow #ACR22 #AI #MachineLearning #AxSpA https://t.co/mXUHUowGhQ

Abstr #0195 examined acceptance of Virtual Reality among pts w/ rheumatic diseases (RD) - VR naïve & experienced were willing to use VR to manage their RD - VR experienced pts had ↑ % of perceived usefulness & anticipated enjoyment of VR in dx and mgmt of RD @RheumNow #ACR22 https://t.co/r7X8Kqp8UN

Abst0338 #ACR22 Transition from CLE to SLE 324 cases of incident cutaneous lupus, mean f/u 8 years 26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years Risk factors: SCLE, younger age, recent diagnosis @RheumNow #ACRBest https://t.co/JFcUIkfA9n

Ab1291 #ACR22: 🔥Ignite🔥 @DavidLeverenz: Constructed a model to identify telehealth visits - PPV 0.8, sensitivity 0.39 - better than existing practice (PPV 0.77) Predictors: age, diagnoses, medications, RAPID3, provider preference for 💻🩺 3 mo pilot program predictive @RheumNow https://t.co/Iey87SVGv4

Very important point about statin induced myopathy by Dr. Christopher-Stine. If 1) history of statin exposure, 2) typical symptoms of myositis 3) HMGCR ab positive — do NOT need biopsy and can treat as statin associated necrotizing autoimmune myopathy! @RheumNow #ACR22 https://t.co/VHxPRkCWwj

Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22 https://t.co/2IikApUdvE https://t.co/16ggVScs3a

SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO